Home » Stocks » Orgenesis

Orgenesis Inc. (ORGS)

Stock Price: $5.60 USD 0.14 (2.56%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 123.18M
Revenue (ttm) 34.72M
Net Income (ttm) -65.76M
Shares Out 22.00M
EPS (ttm) 3.37
PE Ratio 1.66
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $5.60
Previous Close $5.46
Change ($) 0.14
Change (%) 2.56%
Day's Open 5.46
Day's Range 5.35 - 5.70
Day's Volume 27,748
52-Week Range 2.35 - 8.20

More Stats

Market Cap 123.18M
Enterprise Value 36.43M
Earnings Date (est) Oct 19, 2020
Ex-Dividend Date n/a
Shares Outstanding 22.00M
Float 17.38M
EPS (basic) 6.04
EPS (diluted) 3.37
FCF / Share -1.78
Dividend n/a
Dividend Yield n/a
Earnings Yield 60.18%
FCF Yield n/a
Payout Ratio n/a
Shares Short 697,009
Short Ratio 2.69
Short % of Float 3.32%
Beta 1.38
PE Ratio 1.66
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.55
PB Ratio 1.36
Revenue 34.72M
Operating Income -44.75M
Net Income -65.76M
Free Cash Flow -38.18M
Net Cash 86.74M
Net Cash / Share 3.94
Gross Margin 43.28%
Operating Margin -128.89%
Profit Margin -301.30%
FCF Margin -109.99%
ROA -15.09%
ROE -54.17%
ROIC -273.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$9.00*
Low
9.00
Current: $5.60
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue33.2618.6610.096.402.97-----
Revenue Growth78.27%84.9%57.71%115.1%------
Gross Profit15.027.833.28-1.26-0.91-----
Operating Income-24.83-16.85-10.02-11.28-7.21-4.58-5.46-4.99-0.07-0.04
Net Income-24.12-18.29-12.37-11.11-4.46-5.50-5.54-5.00-0.07-0.04
Shares Outstanding15.9113.379.688.524.654.514.214.526.716.71
Earnings Per Share1.771.43-1.31-1.30-1.32-1.32-1.32-1.08--
EPS Growth23.78%---------
Operating Cash Flow-13.22-15.68-3.83-3.78-2.71-1.43-1.99-1.05--0.01
Capital Expenditures-12.05-5.56-0.98-1.43-0.98-0.01-0.01-0.01--
Free Cash Flow-25.27-21.24-4.81-5.21-3.69-1.43-2.00-1.06--0.01
Cash & Equivalents0.570.003.520.894.171.310.060.010.000.00
Total Debt13.76-7.699.8510.282.450.26---
Net Cash / Debt-13.190.00-4.17-8.96-6.11-1.14-0.200.010.000.00
Assets92.50-39.8733.4938.752.250.110.05--
Liabilities55.46-22.1420.9923.735.232.150.330.090.01
Book Value5.48-14.1212.50-6.44-2.98-2.03-0.28-0.08-0.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Orgenesis Inc.
Country United States
Employees 309
CEO Vered Caplan

Stock Information

Ticker Symbol ORGS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ORGS

Description

Orgenesis Inc., a biotechnology company, engages in the development, manufacturing, and provision of cell and gene therapies through point-of-care solutions. The company's point-of-care cell therapy platform focuses on the development of proprietary cell and gene therapies, including Advanced Therapy Medicinal Products (ATMPs) through its autologous trans-differentiation technology. It offers therapies for a range of treatments, including cell-based immunotherapies, metabolic diseases, neurodegenerative diseases, and tissue regeneration. In addition, the company provides regulatory services, pre-clinical studies, intellectual property services, and co-development services. Orgenesis Inc. has various collaboration and license agreements with Adva Biotechnology Ltd.; Tel Hashomer Medical Research, Infrastructure and Services Ltd; Mircod Limited; HekaBio K.K; Image Securities Ltd.; Hemogenyx Pharmaceuticals PLC.; Immugenyx LLC.; BG Negev Technologies and Applications; Cure Therapeutics; Tarus Therapeutics, Inc.; ExcellaBio Ltd.; Infantil Universitario Niño Jesús; and Columbia University, as well as a joint venture agreement with RevaTis S.A. to develop autologous therapies. It also has a clinical study agreement with The Edith Wolfson Medical Center to conduct clinical study using Orgenesis' proprietary POCare technologies for the generation and expansion of tumor infiltrating lymphocytes. The company was formerly known as Business Outsourcing Services, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.